Trial Profile

Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN Treatment

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2024 According to the BioXcel Therapeutics Media Release, This study showed the 180 mcg dose worked without losing effectiveness or causing withdrawal, reducing agitation over a week without serious side effects, These results support the ongoing Phase 3 SERENITY and TRANQUILITY programs.
25 Jun 2024 According to the BioXcel Therapeutics Media Release, the company looks forward to sharing these IGALMI PMR data with FDA.
25 Jun 2024 Positive topline results presented in the BioXcel Therapeutics Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com